EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study

Sarah F Hak, Roderick P Venekamp iD, Marie-Noëlle Billard iD, Daniela Cianci, Marlies A Van Houten, Andrew J Pollard, Terho Heikkinen, Steve Cunningham iD, Margaret Millar, Federico Martinon-Torres, Ana Dacosta-Urbieta, Louis J Bont und 2 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf123 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Sarah F Hak und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlan…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Respiratory Syncytial Virus Infections, Respiratory Tract Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative 2 Joint Undertaking, EU's Horizon 2020 research and innovation programme, European Federation of Pharmaceutical Industries and Associations.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early-life antibiotic use impacts microbiome composition and contributes to the emergence of antimicrobial resistance. Despite respiratory syncytial virus (RSV) being a leading cause of acute respiratory infections (ARI), accurate estimates of antibiotic use attributable to RSV are lacking.

Objectives

To assess RSV-associated antibiotic use during the first year of life. Patients and methods The RESCEU birth cohort study followed healthy term infants, born (n = 9154) between 1 July 2017 and 31 July 2020 from five European countries, to identify RSV-ARI hospitalizations during infancy. In a nested cohort (n = 993), we performed active RSV surveillance by collecting nasal swabs in case of ARI symptoms during RSV seasons (October–April). Antibiotic use during hospitalization was identified through chart review, while outpatient data were collected via parental questionnaires.

Results

In the total cohort, antibiotics were used in 22.8% of RSV hospitalizations (33/145) and 62.5% of RSV intensive care admissions (5/8). In the nested cohort, antibiotics were used in 5.2% of any-severity RSV-ARI (13/250) and 9.9% of medically attended RSV-ARI (13/131). This results in an estimated incidence of 1.3% (95%CI: 0.8–2.0) of healthy term infants receiving ≥1 course of antibiotics associated with RSV infection in their first year, with an incidence rate of 1.1 RSV-associated antibiotic prescriptions per 1000 infant-months (95%CI: 0.6–1.9). As such, RSV accounts for 22.9% of antibiotic prescriptions for ARI during RSV seasons.

Conclusions

One in 77 healthy term infants receives antibiotics during RSV infection before their first birthday. Real-world evidence is needed to establish the impact of RSV immunization on antibiotic use during infancy. Clinical Trials Registration NCT03627572.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsFemaleHumansInfantInfant, NewbornMaleBirth CohortEuropeHospitalizationIncidenceProspective StudiesRespiratory Syncytial Virus, Human

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlands.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Data Science and Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Paediatrics, Spaarne Gasthuis Academy, Hoofddorp and Haarlem, The Netherlands.
  • Department of Paediatrics, Oxford Vaccine Group, University of Oxford, and the NIHR Oxford, Biomedical Research Centre, Oxford, UK.
  • Department of Pediatrics, University of Turku and Turku University Hospital, Turku, Finland.

ORCID-Profile: Roderick P Venekamp, Marie-Noëlle Billard, Steve Cunningham

Förderung

  • Innovative Medicines Initiative 2 Joint Undertaking
  • EU's Horizon 2020 research and innovation programme
  • European Federation of Pharmaceutical Industries and Associations
  • EU’s Horizon 2020 research and innovation programme

Zitieren

APA

Hak, S. F., Venekamp, R. P., Billard, M. N., Cianci, D., Van Houten, M. A., Pollard, A. J., Heikkinen, T., Cunningham, S., Millar, M., Martinon-Torres, F., Dacosta-Urbieta, A., Bont, L. J., Wildenbeest, J. G., & PROMISE Investigators (2025). Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf123

Vancouver

Hak SF, Venekamp RP, Billard MN, Cianci D, Van Houten MA, Pollard AJ, et al. Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf123

BibTeX
@article{Hak2025,
  author = {Hak, Sarah F and Venekamp, Roderick P and Billard, Marie-Noëlle and Cianci, Daniela and Van Houten, Marlies A and Pollard, Andrew J and Heikkinen, Terho and Cunningham, Steve and Millar, Margaret and Martinon-Torres, Federico and Dacosta-Urbieta, Ana and Bont, Louis J and Wildenbeest, Joanne G and PROMISE Investigators, PROMISE Investigators},
  title = {Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf123}
}
Kostenlos starten →